1-10 of 10
Stephen L. George
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

Clinical Trials & Observations
Marc Buyse, Pierre Squifflet, Beverly J. Lange, Todd A. Alonzo, Richard A. Larson, Jonathan E. Kolitz, Stephen L. George, Clara D. Bloomfield, Sylvie Castaigne, Sylvie Chevret, Didier Blaise, Dominique Maraninchi, Kathryn J. Lucchesi, Tomasz Burzykowski
Journal: Blood
Blood (2011) 117 (26): 7007–7013.
https://doi.org/10.1182/blood-2011-02-337725
Published: 2011
Includes: Supplemental data
Journal Articles

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Clinical Trials & Observations
Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hars, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson, for the Cancer and Leukemia Group B
Journal: Blood
Blood (2010) 116 (9): 1413–1421.
https://doi.org/10.1182/blood-2009-07-229492
Published: 2010
Journal Articles

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

Jonathan E. Kolitz, Vera Hars, Daniel J. DeAngelo, Steven L. Allen, Thomas C. Shea, Ravi Vij, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Stephen L. George, Richard A. Larson
Journal: Blood
Blood (2007) 110 (11): 157.
https://doi.org/10.1182/blood.V110.11.157.157
Published: 2007
Journal Articles

Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients ≥60 Years (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Ben L. Sanford, MS, Sandra M. Bothun, BS, Krzysztof Mrozek, PhD, Kieran L. O’Loughlin, BS, Jonathan E. Kolitz, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Bayard L. Powell, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD
Journal: Blood
Blood (2007) 110 (11): 296.
https://doi.org/10.1182/blood.V110.11.296.296
Published: 2007
Journal Articles

Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).

Maria R. Baer, MD, Stephen L. George, PhD, Michael A. Caligiuri, MD, Ben L. Sanford, MS, Kieran L. O’Loughlin, MS, Krysztof Mrozek, PhD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Joseph O. Moore, MD, Richard M. Stone, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD
Journal: Blood
Blood (2006) 108 (11): 424.
https://doi.org/10.1182/blood.V108.11.424.424
Published: 2006
Journal Articles

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas Shea, Wendy Stock, Vera Hars, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson
Journal: Blood
Blood (2005) 106 (11): 407.
https://doi.org/10.1182/blood.V106.11.407.407
Published: 2005
Journal Articles

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Clinical Trials & Observations
Joseph O. Moore, Stephen L. George, Richard K. Dodge, Philip C. Amrein, Bayard L. Powell, Jonathan E. Kolitz, Maria R. Baer, Frederick R. Davey, Clara D. Bloomfield, Richard A. Larson, Charles A. Schiffer
Journal: Blood
Blood (2005) 105 (9): 3420–3427.
https://doi.org/10.1182/blood-2004-08-2977
Published: 2005
Journal Articles

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

Clinical Trials & Observations
Maria R. Baer, Stephen L. George, Richard K. Dodge, Kieran L. O'Loughlin, Hans Minderman, Michael A. Caligiuri, John Anastasi, Bayard L. Powell, Jonathan E. Kolitz, Charles A. Schiffer, Clara D. Bloomfield, Richard A. Larson
Journal: Blood
Blood (2002) 100 (4): 1224–1232.
https://doi.org/10.1182/blood.V100.4.1224.h81602001224_1224_1232
Published: 2002
Journal Articles

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

Clinical Trials & Observations
Richard M. Stone, Deborah T. Berg, Stephen L. George, Richard K. Dodge, Paolo A. Paciucci, Philip P. Schulman, Edward J. Lee, Joseph O. Moore, Bayard L. Powell, Maria R. Baer, Clara D. Bloomfield, Charles A. Schiffer
Journal: Blood
Blood (2001) 98 (3): 548–553.
https://doi.org/10.1182/blood.V98.3.548
Published: 2001
Journal Articles

A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111

Richard A. Larson, Richard K. Dodge, Charles A. Linker, Richard M. Stone, Bayard L. Powell, Edward J. Lee, Philip Schulman, Frederick R. Davey, Stanley R. Frankel, Clara D. Bloomfield, Stephen L. George, Charles A. Schiffer
Journal: Blood
Blood (1998) 92 (5): 1556–1564.
https://doi.org/10.1182/blood.V92.5.1556
Published: 1998